Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics
- PMID: 32386099
- DOI: 10.1111/jvh.13317
Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics
Abstract
Over 3 million paediatric patients globally and ~50 000 in the United States are estimated to be infected with HCV. Eradicating HCV in children helps prevent liver fibrosis, cirrhosis and hepatocellular carcinoma; reduces extra-hepatic manifestations of HCV; improves quality of life; and increases survival. The 2019 American Association for the Study of Liver Diseases-Infectious Diseases Society of America (AASLD-IDSA) guidelines now recommend direct-acting antiviral (DAA) treatment with an approved regimen for all children and adolescents with HCV infection aged ≥3 years. We conducted a descriptive review of the new DAA treatments for HCV infection in the paediatric population. Ledipasvir/sofosbuvir (LDV/SOF) and sofosbuvir with ribavirin (SOF/RBV) are now approved for those ≥3 years old under specific clinical scenarios; sofosbuvir/velpatasvir (SOF/VEL) is the only pangenotypic agent approved for those ≥6 years or ≥17 kg, and glecaprevir/pibrentasvir (GLE/PIB) is approved for adolescents ≥12 years old or ≥45 kg. These DAA regimens are well-tolerated and have comparable sustained virologic response rates at 12 weeks post-treatment compared to those reported in adults (close to 100%). The introduction of DAAs has significantly changed the landscape of HCV treatment in adults and children with HCV infection and has increased confidence that the 2030 World Health Organization elimination goal may be attainable. Further studies are warranted to determine the optimal treatment for children with HCV infection, including timing, regimen and duration. Additionally, with the recent paediatric approvals, long-term safety data are needed.
Keywords: elimination; hepatitis c; pediatric.
© 2020 John Wiley & Sons Ltd.
Similar articles
-
Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.J Viral Hepat. 2020 Sep;27(9):866-872. doi: 10.1111/jvh.13305. Epub 2020 May 12. J Viral Hepat. 2020. PMID: 32343472
-
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.Aliment Pharmacol Ther. 2024 Jul;60(2):201-211. doi: 10.1111/apt.18020. Epub 2024 May 2. Aliment Pharmacol Ther. 2024. PMID: 38695095
-
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.Korean J Gastroenterol. 2024 Mar 25;83(3):111-118. doi: 10.4166/kjg.2023.141. Korean J Gastroenterol. 2024. PMID: 38522854
-
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.Adv Ther. 2020 Sep;37(9):4033-4042. doi: 10.1007/s12325-020-01449-0. Epub 2020 Aug 4. Adv Ther. 2020. PMID: 32754824 Free PMC article. Review.
-
Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis.Ann Hepatol. 2021 Jul-Aug;23:100268. doi: 10.1016/j.aohep.2020.09.012. Epub 2020 Oct 12. Ann Hepatol. 2021. PMID: 33059055
Cited by
-
The Role of IL-35 in the Pathophysiological Processes of Liver Disease.Front Pharmacol. 2021 Jan 21;11:569575. doi: 10.3389/fphar.2020.569575. eCollection 2020. Front Pharmacol. 2021. PMID: 33584256 Free PMC article. Review.
-
Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis.Virol J. 2024 Nov 4;21(1):275. doi: 10.1186/s12985-024-02544-2. Virol J. 2024. PMID: 39497140 Free PMC article.
-
Cascade of care for children and adolescents with chronic hepatitis C.World J Gastroenterol. 2021 Mar 28;27(12):1117-1131. doi: 10.3748/wjg.v27.i12.1117. World J Gastroenterol. 2021. PMID: 33828389 Free PMC article. Review.
-
Treatment of Hepatitis C in a Case of Pediatric B-Cell Acute Leukemia.J Glob Infect Dis. 2021 Aug 3;14(1):35-37. doi: 10.4103/jgid.jgid_1_21. eCollection 2022 Jan-Mar. J Glob Infect Dis. 2021. PMID: 35418736 Free PMC article.
-
SARS-CoV-2 infection in a pediatric acute leukemia patient on chemotherapy and concurrent sofosbuvir/velpatasvir for HCV.Am J Blood Res. 2021 Jun 15;11(3):286-289. eCollection 2021. Am J Blood Res. 2021. PMID: 34322293 Free PMC article.
References
REFERENCES
-
- World Health Organization. Global Hepatitis Report 2017. Geneva: WHO; 2017.
-
- Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-176.
-
- World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030. Geneva: World Health Organization; 2016.
-
- Ly KN, Jiles RB, Teshale EH, Foster MA, Pesano RL, Holmberg SD. Hepatitis C virus infection among reproductive-aged women and children in the United States, 2006 to 2014. Ann Intern Med. 2017;166(11):775-782.
-
- Rosenberg ES, Rosenthal EM, Hall EW, et al. Prevalence of hepatitis C virus infection in US States and the District of Columbia, 2013 to 2016. JAMA Netw open. 2018;1(8):e186371.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical